Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II, Open-label, Multi-center Study to Evaluate the Safety and Efficacy of Glyco-humanized Polyclonal Antibody Directed Against Tumoral T Cells, in Patients With Relapsed/Refractory Peripheral T Cells Lymphoma (PTCL)

Next Previous
Trial Profile

Phase I/II, Open-label, Multi-center Study to Evaluate the Safety and Efficacy of Glyco-humanized Polyclonal Antibody Directed Against Tumoral T Cells, in Patients With Relapsed/Refractory Peripheral T Cells Lymphoma (PTCL)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LIS 1 (Primary)
  • Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PALT1
  • Sponsors Xenothera

Most Recent Events

  • 23 Jun 2025 According to a Xenothera media release, The results from this trial will be presented orally on Tuesday June 18 at the World Congress on Lymphoma (18th International Conference on Malignant Lymphoma, Lugano, Switzerland.
  • 16 Jan 2025 According to a Xenothera media release, company announces the trials Scientific Advisory Board approved the switch to a 4mg dose. Three patients are currently being treated at 4mg, and will be followed by 6 patients at 6mg.
  • 16 Jan 2025 According to XENOTHERA Media Release, company successfully secures 4 euros Million non-dilutive financing from the France 2030 Public Investment Plan for its LIS22 treatment for peripheral T-Cell lymphoma and this 4 euros million funding will enable XENOTHERA to conduct the PALT1 clinical trial (NCT06495723), with the aim of obtaining early access authorisation in France and Europe by 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top